P/E ratio for Takeda Pharmaceutical (TAK)
P/E ratio as of June 2024 (TTM): 28.1
According to Takeda Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 28.0928. At the end of 2022 the company had a P/E ratio of 24.0.
P/E ratio history for Takeda Pharmaceutical from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 24.0 | 121.74% |
| 2021 | 10.8 | -67.34% |
| 2020 | 33.1 | -92.87% |
| 2019 | 465 | 1600.53% |
| 2018 | 27.3 | 4.13% |
| 2017 | 26.2 | 2.65% |
| 2016 | 25.6 | -160.7% |
| 2015 | -42.1 | -162.08% |
| 2014 | 67.8 | 165.3% |
| 2013 | 25.6 | -5.69% |
| 2012 | 27.1 | 89.46% |
| 2011 | 14.3 | 10.52% |
| 2010 | 12.9 | 32% |
| 2009 | 9.81 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.3 | -63.28% | 🇺🇸 USA |
 Novartis NVS | 26.9 | -4.16% | 🇨🇭 Switzerland |
 Pfizer PFE | 15.2 | -46.03% | 🇺🇸 USA |
 Amgen AMGN | 21.3 | -24.28% | 🇺🇸 USA |
 Sanofi SNY | 15.0 | -46.46% | 🇫🇷 France |
 Merck MRK | 68.4 | 143.34% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 12.6 | -55.24% | 🇬🇧 UK |
 Seagen
SGEN | -57.0 | -303.05% | 🇺🇸 USA |
 Dr. Reddy's RDY | 18.8 | -32.99% | 🇮🇳 India |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.